Tuesday, 15 September 2015

2015 to 2020 Microscopic Polyangiitis (MPA) Industry, Shares, Strategies, and Forecasts, Worldwide

This report provides comprehensive information on the therapeutic development for Microscopic Polyangiitis (MPA), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Microscopic Polyangiitis (MPA) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.


-The report provides a snapshot of the global therapeutic landscape of Microscopic Polyangiitis (MPA)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Microscopic Polyangiitis (MPA) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Microscopic Polyangiitis (MPA) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Microscopic Polyangiitis (MPA) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Table Of Content

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Microscopic Polyangiitis (MPA) Overview 6
Therapeutics Development 7
Pipeline Products for Microscopic Polyangiitis (MPA) - Overview 7
Pipeline Products for Microscopic Polyangiitis (MPA) - Comparative Analysis 8
Microscopic Polyangiitis (MPA) - Therapeutics under Development by Companies 9
Microscopic Polyangiitis (MPA) - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Microscopic Polyangiitis (MPA) - Products under Development by Companies 13
Microscopic Polyangiitis (MPA) - Companies Involved in Therapeutics Development 14
Aprogen, Inc. 14
ChemoCentryx, Inc. 15
Epirus Biopharmaceuticals, Inc. 16
GlaxoSmithKline Plc 17
Panacea Biotec Limited 18
Sandoz International GmbH 19
Teijin Pharma Limited 20
Microscopic Polyangiitis (MPA) - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30

Request A Sample copy of This Report @ http://www.hexareports.com/sample/46612

belimumab - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
CCX-168 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
immune globulin (human) - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
rituximab biosimilar - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
rituximab biosimilar - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
rituximab biosimilar - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
rituximab biosimilar - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Microscopic Polyangiitis (MPA) - Recent Pipeline Updates 40
Microscopic Polyangiitis (MPA) - Dormant Projects 46
Microscopic Polyangiitis (MPA) - Product Development Milestones 47
Featured News & Press Releases 47
Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis 47
Jun 03, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in ANCA-Associated Diseases by the FDA 47
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 48
Disclaimer 49

About Us:
Hexa Reports is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Information:

Ryan Shaw

Felton Office Plaza,
6265 Highway 9,
Felton, California, 95018,
United States
Phone Number

No comments:

Post a Comment